Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 2
2008 1
2017 2
2018 1
2019 1
2020 3
2021 3
2022 1
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Brain and bone marrow metastases from rectal cancer.
Thomopoulou K, Manolakou S, Messaritakis I, Tzardi M, Lagoudaki E, Koutsopoulos A, Koulouris A, Kanellis G, Kalbakis K, Mavroudis D, Souglakos I. Thomopoulou K, et al. Among authors: kalbakis k. Ann Gastroenterol. 2020 Jan-Feb;33(1):95-97. doi: 10.20524/aog.2019.0423. Epub 2019 Oct 8. Ann Gastroenterol. 2020. PMID: 31892804 Free PMC article.
BRCA1 and BRCA2 germline testing in Cretan isolates reveals novel and strong founder effects.
Apostolou P, Fostira F, Kouroussis C, Kalfakakou D, Delimitsou A, Agelaki S, Androulakis N, Christodoulou C, Kalbakis K, Kalykaki A, Sanidas E, Papadimitriou C, Vamvakas L, Georgoulias V, Mavroudis D, Yannoukakos D, Konstantopoulou I, Saloustros E. Apostolou P, et al. Among authors: kalbakis k. Int J Cancer. 2020 Sep 1;147(5):1334-1342. doi: 10.1002/ijc.32903. Epub 2020 Mar 5. Int J Cancer. 2020. PMID: 32022259 Free article.
Objective Response to First-Line Treatment as a Predictor of Overall Survival in Metastatic Breast Cancer: A Retrospective Analysis from Two Centers over a 25-Year Period.
Matikas A, Kotsakis A, Perraki M, Hatzidaki D, Kalbakis K, Kontopodis E, Nikolaou M, Georgoulias V. Matikas A, et al. Among authors: kalbakis k. Breast Care (Basel). 2022 Jun;17(3):264-271. doi: 10.1159/000519729. Epub 2021 Oct 29. Breast Care (Basel). 2022. PMID: 35949417 Free PMC article.
Correction: Prediction of outcome in patients with non-small cell lung cancer treated with second line PD-1/PDL-1 inhibitors based on clinical parameters: Results from a prospective, single institution study.
Rounis K, Makrakis D, Papadaki C, Monastirioti A, Vamvakas L, Kalbakis K, Gourlia K, Xanthopoulos I, Tsamardinos I, Mavroudis D, Agelaki S. Rounis K, et al. Among authors: kalbakis k. PLoS One. 2023 Nov 9;18(11):e0294382. doi: 10.1371/journal.pone.0294382. eCollection 2023. PLoS One. 2023. PMID: 37943834 Free PMC article.
Prediction of outcome in patients with non-small cell lung cancer treated with second line PD-1/PDL-1 inhibitors based on clinical parameters: Results from a prospective, single institution study.
Rounis K, Makrakis D, Papadaki C, Monastirioti A, Vamvakas L, Kalbakis K, Gourlia K, Xanthopoulos I, Tsamardinos I, Mavroudis D, Agelaki S. Rounis K, et al. Among authors: kalbakis k. PLoS One. 2021 Jun 1;16(6):e0252537. doi: 10.1371/journal.pone.0252537. eCollection 2021. PLoS One. 2021. PMID: 34061904 Free PMC article.
Real-world management practices and characteristics of patients with advanced melanoma initiated on immuno-oncology or targeted therapy in the first-line setting during the period 2015-2018 in Greece. The 'SUMMER' study: a retrospective multicenter chart review project.
Bafaloukos D, Kouzis P, Gouveris P, Boukovinas I, Kalbakis K, Baka S, Kyriakakis G, Moschou D, Molfeta A, Demiri S, Mavroudis D, Spanoudi F, Dimitriadis I, Gogas H. Bafaloukos D, et al. Among authors: kalbakis k. Melanoma Res. 2024 Apr 1;34(2):152-165. doi: 10.1097/CMR.0000000000000949. Epub 2023 Dec 13. Melanoma Res. 2024. PMID: 38092014 Free PMC article.
Cancer cachexia syndrome and clinical outcome in patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors: results from a prospective, observational study.
Rounis K, Makrakis D, Tsigkas AP, Georgiou A, Galanakis N, Papadaki C, Monastirioti A, Vamvakas L, Kalbakis K, Vardakis N, Kontogianni M, Gioulbasanis I, Mavroudis D, Agelaki S. Rounis K, et al. Among authors: kalbakis k. Transl Lung Cancer Res. 2021 Aug;10(8):3538-3549. doi: 10.21037/tlcr-21-460. Transl Lung Cancer Res. 2021. PMID: 34584855 Free PMC article.
Weekly Paclitaxel and Carboplatin Plus Bevacizumab as First-Line Treatment of Metastatic Triple-Negative Breast Cancer. A Multicenter Phase II Trial by the Hellenic Oncology Research Group.
Saloustros E, Nikolaou M, Kalbakis K, Polyzos A, Christofillakis C, Kentepozidis N, Pistamaltzian N, Kourousis C, Vamvakas L, Georgoulias V, Mavroudis D. Saloustros E, et al. Among authors: kalbakis k. Clin Breast Cancer. 2018 Feb;18(1):88-94. doi: 10.1016/j.clbc.2017.10.013. Epub 2017 Oct 24. Clin Breast Cancer. 2018. PMID: 29153775 Clinical Trial.
Circulating MicroRNAs Regulating DNA Damage Response and Responsiveness to Cisplatin in the Prognosis of Patients with Non-Small Cell Lung Cancer Treated with First-Line Platinum Chemotherapy.
Papadaki C, Monastirioti A, Rounis K, Makrakis D, Kalbakis K, Nikolaou C, Mavroudis D, Agelaki S. Papadaki C, et al. Among authors: kalbakis k. Cancers (Basel). 2020 May 19;12(5):1282. doi: 10.3390/cancers12051282. Cancers (Basel). 2020. PMID: 32438598 Free PMC article.
Sequential vs concurrent epirubicin and docetaxel as adjuvant chemotherapy for high-risk, node-negative, early breast cancer: an interim analysis of a randomised phase III study from the Hellenic Oncology Research Group.
Mavroudis D, Saloustros E, Boukovinas I, Papakotoulas P, Kakolyris S, Ziras N, Christophylakis C, Kentepozidis N, Fountzilas G, Rigas G, Varthalitis I, Kalbakis K, Agelaki S, Hatzidaki D, Georgoulias V. Mavroudis D, et al. Among authors: kalbakis k. Br J Cancer. 2017 Jul 11;117(2):164-170. doi: 10.1038/bjc.2017.158. Epub 2017 Jun 22. Br J Cancer. 2017. PMID: 28641315 Free PMC article. Clinical Trial.
14 results